|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||50.71 / 68.12|
Here's your 'silver linings playbook' for what promises to be a nerve-wracking week of unpredictable politics, mixed corporate earnings and volatile energy prices.
- Elagolix shows superiority compared to placebo in reducing daily menstrual and non-menstrual pelvic pain associated with endometriosis
In the near term Abbvie bulls should take a more positive view of the stock.
With Clinton apparently headed for victory, worries about her being a threat to health-care stocks have peaked.
Investors had reduced expectations for Celgene's experimental pill for Crohn's disease, which makes the new clinical data released Sunday night look all right, although doubts will persist.
We continue to believe the company is attractive to buy at 11.2x expected 2017 earnings of $5.64 a share.
Keep an eye on Eaton Vance and these 6 notable dividend must-own dates.
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
- Breakthrough Therapy Designation granted based on Phase 2 clinical data for genotype 1 (GT1) patients who failed previous therapy with direct-acting antivirals (DAAs)
Stock losses accelerate on Thursday as Deutsche Bank and Wells Fargo drag on the financials sector.
- New site to expand the company's global operations for small molecule and biologics manufacturing
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
- New Phase 2 open-label extension data to be presented on investigational biologic compound risankizumab, an anti-IL-23 monoclonal antibody, currently under investigation for moderate to severe chronic plaque psoriasis
- If approved by the U.S. FDA, ibrutinib will be the first therapy specifically approved for patients with marginal zone lymphoma (MZL), a slow-growing form of non-Hodgkin's lymphoma, and the fifth new treatment indication for the medication
- 98 percent of previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVR12 in Phase 3b GARNET study1
AbbVie's impressive move is setting the stage for an upside breakout.
The key is to focus on names with steadily growing earnings and dividends.
AbbVie (ABBV) announced on Tuesday that it would partner with BioArctic Neuroscience to develop and commercialize BioArctic's Parkinson's treatments.
A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA TM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking...
Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?
Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.
Cramer is sticking with International Paper and likes Advanced Micro Devices.